Carregant...
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situ...
Guardat en:
| Publicat a: | J Cardiovasc Pharmacol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779665/ https://ncbi.nlm.nih.gov/pubmed/33165138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000929 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|